Medical writing support was provided by Micah Robinson at Amgen Inc.
See JNCCN.org for supplemental online content.
Xiaoyan Li, Phuong Khanh Morrow, Richard L Barron, Yanli Li, and Jacob Garcia are employed by and own stock in Amgen Inc. Gary H. Lyman is the principal investigator of a research grant to the Fred Hutchinson Cancer Research Center from Amgen. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
This study was funded by Amgen Inc.
Gradishar WJ, Anderson BO, Balassanian R et al.. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2014. Available at: NCCN.org. Accessed December 9, 2014.
Morgan RJ Jr, Armstrong DK, Alvarez RD et al.. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 3.2014. Available at: NCCN.org. Accessed December 9, 2014.
Ettinger DS, Wood DE, Akerley W et al.. NCCN Clinical Practice Guidelines in Oncology: Non–Small Cell Lung Cancer. Version 1.2015. Available at: NCCN.org. Accessed December 9, 2014.
Hoppe RT, Advani RH, Ai WZ et al.. NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. Version 2.2014. Available at: NCCN.org. Accessed December 9, 2014.
Zelenetz AD, Gordon LI, Wierda WG et al.. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. Version 5.2014. Available at: NCCN.org. Accessed December 9, 2014.
Benson AB III, Venook AP, Bekaii-Saab T et al.. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2015. Available at: NCCN.org. Accessed December 9, 2014.
Benson AB III, Venook AP, Bekaii-Saab T et al.. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 2.2015. Available at: NCCN.org. Accessed December 9, 2014.
Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524–4531.
Crawford J, Dale DC, Kuderer NM et al.. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008;6:109–118.
Lyman GH, Dale DC, Friedberg J et al.. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:4302–4311.
Pettengell R, Schwenkglenks M, Leonard R et al.. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008;16:1299–1309.
Bonadonna G, Valagussa P, Moliterni A et al.. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901–906.
Bosly A, Bron D, Van Hoof A et al.. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2008;87:277–283.
Chirivella I, Bermejo B, Insa A et al.. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 2009;114:479-484.
Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963–977.
Osby E, Hagberg H, Kvaloy S et al.. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840–3848.
Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 2011;77:221–240.
Havrilesky LJ, Hanna RK, Poniewierski MS et al.. Relationship between relative dose intensity and mortality in women receiving combination chemotherapy for stage III-IV epithelial ovarian cancer [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 5084.
Hanna RK, Poniewierski MS, Laskey RA et al.. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol 2013;129:74–80.
Budman DR, Berry DA, Cirrincione CT et al.. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205–1211.
Lyman GH, Dale DC, Tomita D et al.. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. Breast Cancer Res Treat 2013;139:863–872.
Hryniuk WM, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 1987;14(4 Suppl 4):3–11.
Foote M. The Importance of planned dose of chemotherapy on time: do we need to change our clinical practice? Oncologist 1998;3:365–368.
Balducci L, Al-Halawani H, Charu V et al.. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007;12:1416–1424.
Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158–3167.
Lyman GH, Crawford J, Tomita D et al.. Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2015:1–8.
Weycker D, Barron R, Edelsberg J et al.. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res Treat 2012;133:301–310.
Crawford J, Becker PS, Armitage JO et al.. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. Version 2.2014. Available at: NCCN.org. Accessed December 9, 2014.
Hurria A, Wong FL, Villaluna D et al.. Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers. J Clin Oncol 2008;26:5386–5392.
Kornblith AB, Kemeny M, Peterson BL et al.. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 2002;95:989–996.
Citron ML, Berry DA, Cirrincione C et al.. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431–1439.
- Search Google Scholar
- Export Citation
. Citron ML Berry DA Cirrincione C Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431– 1439.
Hurria A, Hurria A, Brogan K et al.. Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. Drugs Aging 2005;22:785–791.
van de Water W, Markopoulos C, van de Velde CJ et al.. Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 2012;307:590–597.
Griggs JJ, Mangu PB, Anderson H et al.. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012;30:1553–1561.
Lyman GH, Sparreboom A. Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol 2013;10:451–459.
Muss HB, Woolf S, Berry D et al.. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293:1073–1081.
Shayne M, Culakova E, Wolff D et al.. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer 2009;115:5319–5328.
Gajra A, Klepin HD, Feng T et al.. Predictors of chemotherapy dose reduction at first cycle in patients age 65years and older with solid tumors. J Geriatr Oncol 2015;6:133–140.
Greer JA, Pirl WF, Park ER et al.. Behavioral and psychological predictors of chemotherapy adherence in patients with advanced non-small cell lung cancer. J Psychosom Res 2008;65:549–552.
Repetto LCIPOMO Investigators. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey. Crit Rev Oncol Hematol 2009;72:170–179.
Elting LS, Rubenstein EB, Martin CG et al.. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 2001;19:1137–1146.
Mucke M, Mochamat, Cuhls H et al.. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2015;5:CD006788.
Basch E, Prestrud AA, Hesketh PJ et al.. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189–4198.
Speck RM, Sammel MD, Farrar JT et al.. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract 2013;9:e234–240.
Lalla RV, Bowen J, Barasch A et al.. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014;120:1453–1461.
Culakova E, Thota R, Poniewierski MS et al.. Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med 2014;3:434–444.